|
 |
10-08-2010 Press Release - NsGene and Biogen Idec sign new commercialisation and license agreement on Neublastin.
NsGene and Biogen Idec sign new commercialisation and license agreement on Neublastin,
a novel therapeutic protein in clinical development for neurop...
|
|
|
|
03-09-2009 Neublastin enters Phase I clinical development as a novel treatment for neuropathic pain
NsGene A/S today announced that Neublastin, a proprietary therapeutic protein that NsGene has out-licensed to Biogen Idec [NASDAQ: BIIB] in the field ...
|
|
|
|
19-05-2009 NsGene granted European Patent Rights to its Novel Neurotrophic Factor Meteorin for the Treatment of Neurological Disorders
NsGene A/S today announced that it has been granted European Patent No. EP 1 745 069 B1, covering the novel neurotrophic factor Meteorin (NsG33). Mete...
|
|
|
|
20-05-2008 Capital Infusion and New Chairman
NsGene A/S raises 40 million DKK and appoints Mats Pettersson as new Chairman of the Board.
Capital Infusion of DKK 40 million to NsGene from its S...
|
|
|
|
07-04-2008 Danish biotech company’s restorative Alzheimer’s product has successfully been implanted in patients
NsGene A/S today announced that its encapsulated cell (EC) biodelivery product, NsG0202, has successfully been implanted into the brains of three pati...
|
|
|
|
12-12-2007 NsGene A/S begins Phase Ib clinical trial with NsG0202 for the treatment of Alzheimer’s disease
NsGene A/S announced today that its Clinical Trial Application (CTA) to start a phase Ib study of NsG0202 for Alzheimer’s disease (AD) has been approv...
|
|
|
|
01-03-2007 Capital Infusion of DKK 40 million to NsGene from its Shareholders
News - In order to secure the financing of the current R&D efforts, the Company received DKK 25 million in November 2006 as the first instalment of a ...
|
|
|
|
06-02-2007 News - NsGene participates in an EU funded FP6 project looking at Functional Genomics and Neurobiology of Epilepsy
NsGene participates in an EU funded FP6 project looking at Functional Genomics and Neurobiology of Epilepsy - a Basis for New Therapeutic Strategies
|
|
|
|
12-12-2006 News - NsGene Announces New Board Member, Yvonne Mårtensson
NsGene announces today that Yvonne Mårtensson has been appointed to its Board of Directors. Yvonne Mårtensson currently holds a position as CEO of Cel...
|
|
|
|
28-11-2006 Press Release - NsGene’s proprietary neurotrophic factor, NsG33, will be evaluated by Genzyme for the treatment of motor neuron diseases
Today NsGene announced that an option agreement on NsG33, a novel neurotrophic protein, has been executed with Genzyme Corporation. Under this Option ...
|
|
|
|
24-05-2006 News - NsGene has been awarded an EU R&D project of value for NsGene's proprietary EC Biodelivery technology.
NsGene A/S has, together with nine academic partners, been awarded an EU R&D project, which could prove valuable for NsGene's proprietary Encapsulated...
|
|
|
|
25-10-2005 News - Successful development of Neublastin triggers milestone payment to NsGene A/S
NsGene A/S today announced that NsGene has received a milestone payment from Biogen Idec, Inc. (NASDAQ: BIIB) in accordance with the advancement of th...
|
|
|
|
02-05-2005 Press Release - NsGene A/S moves towards clinical development with an additional DKK 30 million and introduces a new investor.
NsGene A/S today announced the closing of a financing round of DKK 30 million. The financing is structured in two payments and enables NsGene to move ...
|
|
|
|
10-11-2004 News - NsGene's ECT biodelivery technology being evaluated by Genzyme
NsGene A/S and Genzyme Corporation have entered into an agreement under which Genzyme will evaluate NsGene’s ECT Biodelivery technology to deliver to ...
|
|
|
|
02-11-2004 Press release - NsGene’s proprietary protein Neublastin has advanced into development for treatment of neuropathic pain.
NsGene A/S today announced that Biogen Idec (NASDAQ: BIIB) has moved Neublastin, NsGene’s proprietary protein, from research into development for trea...
|
|
|
|
05-07-2004 Press Release - US $3 million Michael J. Fox Foundation grant can yield breakthrough for treatment of Parkinson's disease.
NsGene announced today that the Michael J. Fox Foundation for Parkinson's Research (MJFF) has granted US $3 million to support a clinical "proof-of-co...
|
|
|
|
18-05-2004 Press release - US Patent Granted for Protein Important for Treating Neuropathic Pain
NsGene A/S today announced that it has been granted US Patent No. 6,734,284 covering the neurotrophic factor Neublastin. In July 2003, NsGene A/S was ...
|
|
|
|
22-04-2004 Press Release - NsGene A/S announces New Board Member - Dr. Søren Mouritsen, M.D. D.MSc.
Dr. Mouritsen has over 14 years of executive management experience in the biotechnology industry and over 20 years of professional experience in the p...
|
|
|
|
29-12-2003 Press Release - NsGene A/S raises DKK 18 million in a second round of financing from existing investors.
NsGene A/S has closed a second round of private equity funding of DKK 18 million from existing investors. The financing round had contributions from N...
|
|
|
|
09-09-2003 News - Capital infusion of DKK 15 million to ZGene A/S
The Danish biotechnological company ZGene, which NsGene A/S is a co-owner of, raises seed capital of DKK 15 million from Symbion Capital I A/S and Dan...
|
|
|
|
09-05-2003 Press Release - NsGene A/S obtains an exclusive license to encapsulated cell technology (ECT) for the nervous system
On April 9, 2003 NsGene A/S and Neurotech SA, both privately held biotechnology companies, signed a revised license agreement, which expands the right...
|
|
|
|
29-04-2003 Press Release - NsGene has been granted US patent No. 6,555,674, JeT promoter.
NsGene A/S was today granted US patent no. 6,555,674 covering the JeT promoter. The JeT promoter is a strong, synthetic, and compact mammalian promote...
|
|
|
|
02-01-2003 News - NsGene has moved to new premises.
NsGene A/S has, since its establishment in December 1999, been situated in the domicile of NeuroSearch from which it emerged. This enabled a running s...
|
|
|
|
06-12-2002 News - NsGene is awarded an EU R&D project grant with a budget of € 2,3 million.
Together with five academic partners, NsGene A/S has been awarded an EU R&D project under the European Commission Fifth Framework Programme on the sub...
|
|
|
|
14-02-2002 Press Release - NsGene A/S and ZGene A/S enter a license agreement on kinase technology for development of improved cancer treatments.
NsGene A/S has signed an exclusive worldwide license agreement, with the rights to sublicense, with ZGene A/S to develop ultra-fast deoxyribonucleosid...
|
|
|
|
01-12-2001 News - NsGene A/S Strengthens the Management Group.
Dr. Mette Grønborg received her Ph.D. from the University of Copenhagen in 1994 and was part of the original research group that was spun off from Neu...
|
|
|
|
01-11-2001 News - NsGene is awarded an EU R&D project grant as coordinator.
Together with four academic partners, NsGene A/S has been awarded an EU R&D project under the Fifth European Community Framework Programme covering ...
|
|
|
|
|
